Literature DB >> 19371356

Pi3K-mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors.

Karin Boer1, Dirk Troost, Wendy Timmermans, Peter C van Rijen, Wim G M Spliet, Eleonora Aronica.   

Abstract

Gangliogliomas (GGs) and dysembryoplastic neuroepithelial tumors (DNTs) represent the most frequent type of neoplasms in pediatric medically intractable epilepsy. Several data suggest a pathogenetic relationship between GGs and other glioneuronal malformations of cortical development (MCDs), including activation of the Pi3K-mTOR signaling pathway. To further reveal these pathogenetic similarities, we investigated immunocytochemically the expression of phosphorylated (p)-PDK1, p-AKT, p-mTOR, p-4E-BP1, p-eIF4G, p-p70S6K and p-S6, the effector proteins ERM (ezrin/radixin/moesin) and the pathway regulator AMOG (adhesion molecule on glia) in both GGs and DNTs. Components of the Pi3K-mTOR signaling pathway were observed in a higher percentage of neuronal cells in GGs compared with control cortex. In DNTs, the expression of these components was low and comparable with the expression in control samples. Strong immunoreactivity for ERM was observed in GGs, but not in DNTs. Additionally, AMOG was strongly expressed within GGs (but not in DNTs) in CD34-positive precursor cells. These findings support the previously suggested pathogenic relationship between GG and MCDs concerning activation of the Pi3K-mTOR signaling pathway and suggest a different pathogenetic origin for DNTs. The strong expression of AMOG within the precursor cells of GG may represent an additional marker for the diagnostic evaluation of these glioneuronal lesions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371356     DOI: 10.1111/j.1750-3639.2009.00268.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  22 in total

1.  Subunit isoform selectivity in assembly of Na,K-ATPase α-β heterodimers.

Authors:  Elmira Tokhtaeva; Rebecca J Clifford; Jack H Kaplan; George Sachs; Olga Vagin
Journal:  J Biol Chem       Date:  2012-06-13       Impact factor: 5.157

Review 2.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 3.  Malformations of cortical development and epilepsy.

Authors:  A James Barkovich; William B Dobyns; Renzo Guerrini
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

Review 4.  mTOR inhibition in epilepsy: rationale and clinical perspectives.

Authors:  Adam P Ostendorf; Michael Wong
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

5.  Cerebellar Ganglioglioma in Childhood: Histopathologic Implications for Management During Long-term Survival: A Case Report.

Authors:  Koyo Ohno; Yoshiaki Saito; Akiko Tamasaki-Kondo; Atsushi Kambe; Yasushi Horie; Shinsuke Kato; Yoshihiro Maegaki
Journal:  Yonago Acta Med       Date:  2018-02-05       Impact factor: 1.641

6.  Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset.

Authors:  Mark Jentoft; Caterina Giannini; Ling Cen; Bernd W Scheithauer; Bridget Hoesley; Jann N Sarkaria; Patrice C Abell-Aleff; Erika F Rodriguez; Ying Li; Fausto J Rodriguez
Journal:  Int J Clin Exp Pathol       Date:  2010-12-12

Review 7.  Epilepsy related to developmental tumors and malformations of cortical development.

Authors:  Eleonora Aronica; Peter B Crino
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

8.  What is New in the Management of Epilepsy in Gliomas?

Authors:  Roberta Rudà; Riccardo Soffietti
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

Review 9.  The mTOR signalling cascade: paving new roads to cure neurological disease.

Authors:  Peter B Crino
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

Review 10.  A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials.

Authors:  Michael Wong
Journal:  Expert Rev Neurother       Date:  2013-06       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.